# Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

> **NCT02673398** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 25 (actual)

## Conditions studied

- HER2 Positive Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **OTHER:** Comprehensive Geriatric Assessment
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Neratinib
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02673398
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-02
- **Primary completion:** 2020-03-12
- **Final completion:** 2022-09-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673398, "Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02673398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*